Septerna Stock Surges on Oral Obesity Drug Deal With Novo NordiskZacks Investment Research • 05/15/25
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapiesProactive Investors • 05/14/25
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes DrugsBenzinga • 05/14/25
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna SkyrocketingInvestors Business Daily • 05/14/25
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatmentsReuters • 05/14/25
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to knowCNBC • 05/12/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25
Novo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal?Proactive Investors • 05/12/25
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'The Guardian • 05/12/25
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESEGlobeNewsWire • 05/12/25